CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

MITRA-FR vs. COAPT: Lessons from two trials with diametrically opposed results Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure Results From the CABANA Trial Does pulsed field ablation regress over time? A quantitative temporal analysis of pulmonary vein isolation Percutaneous Left Atrial Appendage Occlusion for Patients in Atrial Fibrillation Suboptimal for Warfarin Therapy: 5-year Results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study Current Status and Future Prospects of Transcatheter Mitral Valve Replacement: JACC State-of-the-Art Review The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC Prospective Evaluation of Transseptal TMVR for Failed Surgical Bioprostheses: MITRAL Trial Valve-in-Valve Arm 1-Year Outcomes 2015 ACC/HRS/SCAI Left Atrial Appendage Occlusion Device Societal Overview Systematic Review and Network Meta‐Analysis Comparing Bifurcation Techniques for Percutaneous Coronary Intervention Single direct oral anticoagulant therapy in stable patients with atrial fibrillation beyond 1 year after coronary stent implantation

Guideline2016 Jan 1;37(1):67-119.

JOURNAL:Eur Heart J. Article Link

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)

Galiè N, Humbert M, ESC Scientific Document Group. Keywords: Chronic thromboembolic pulmonary hypertension; Congenital heart disease; Connective tissue disease; Endothelin receptor antagonists; Guidelines; Heart failure; Left heart disease; Lung disease; Phosphodiesterase type 5 inhibitors; Prostacyclin analogues; Pulmonary arterial hypertension; Pulmonary hypertension; Respiratory failure

Full Text PDF